Psyence Biomedical Ltd.
PBM
$0.5168
-$0.0165-3.09%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 382.13% | 147.81% | -0.39% | -1.88% | -27.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 556.70% | 32.09% | -49.78% | -51.20% | -31.12% |
| Operating Income | -556.70% | -32.09% | 49.78% | 51.20% | 31.12% |
| Income Before Tax | 145.69% | 284.30% | -1,835.90% | -1,834.17% | -20.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 145.69% | 284.30% | -1,835.90% | -1,834.17% | -20.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 145.69% | 284.30% | -1,835.90% | -1,834.17% | -20.74% |
| EBIT | -556.70% | -32.09% | 49.78% | 51.20% | 31.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 129.47% | 133.41% | -622.83% | -- | -- |
| Normalized Basic EPS | -200.89% | -- | 90.67% | -- | -- |
| EPS Diluted | 129.40% | 133.41% | -622.83% | -- | -- |
| Normalized Diluted EPS | -200.80% | -- | 90.67% | -- | -- |
| Average Basic Shares Outstanding | 55.01% | -- | 167.62% | -- | -- |
| Average Diluted Shares Outstanding | 55.07% | 245.88% | 167.62% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |